IQVIA’s fourth quarter was marked by solid top-line growth, surpassing Wall Street’s revenue expectations. However, the market reacted negatively, focusing on margin compression and concerns about the ...
How little noise did IQVIA make about its recent highly significant acquisition of Throtle? The change in ownership is noted in a single sentence on the “About” page on Throtle’s website: “Throtle Inc ...
IQVIA provides a broad range of services to biopharma customers, including outsourced R&D services in support of clinical trials. Recent spending caution and the end of COVID-related revenue have led ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and ...
IQVIA is unveiling a new suite of tools designed to manage all the financial components of clinical trials. The company is using an artificial-intelligence-enabled platform to help remove ...
Ron Bruehlman to become Senior Advisor to CEO; Michael Fedock Named as New CFO “Ron has been a cornerstone of IQVIA’s transformation and growth,” said Ari Bousbib. “His strategic leadership and ...
A U.S. judge has upheld the Federal Trade Commission’s (FTC) decision to block IQVIA’s long-running attempt to buy the owner of pharma digital ad specialist DeepIntent. The long-running saga centers ...
Hosted on MSN
IQVIA (NYSE:IQV) Beats Q3 Sales Expectations
Clinical research company IQVIA (NYSE: IQV) reported in Q3 CY2025, with sales up 5.2% year on year to $4.1 billion. The company expects the full year’s revenue to be around $16.2 billion, close to ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results